Prognostic value of automated KI67 scoring in breast cancer: A centralised evaluation of 8088 patients from 10 study groups

Breast Cancer Research

Volumn 18, Issue 1, 2016, Pages

  Abubakar, Mustapha ^a   Orr, Nick ^a   Daley, Frances ^a   Coulson, Penny ^a   Ali, H Raza ^b   Blows, Fiona ^b   Benitez, Javier ^c,d   Milne, Roger ^e,f   Brenner, Herman ^g   Stegmaier, Christa ^h   Mannermaa, Arto ^i,j   Chang Claude, Jenny ^g,k   Rudolph, Anja ^g   Sinn, Peter ^l   Couch, Fergus J ^m   Devilee, Peter ⁿ   Tollenaar, Rob A E M ⁿ   Seynaeve, Caroline ^o   Figueroa, Jonine ^p   Sherman, Mark E ^q   Lissowska, Jolanta ^r   Hewitt, Stephen ^q   Eccles, Diana ^s   Hooning, Maartje J ^o   Hollestelle, Antoinette ^o   Martens, John W M ^o   Deurzen, Carolien H M ^o   Investigators, kConFab ^t   Bolla, Manjeet K ^b   Wang, Qin ^b   Jones, Michael ^a   Schoemaker, Minouk ^a   Wesseling, Jelle ^u   van Leeuwen, Flora E ^u   Van 't Veer, Laura ^u   Easton, Douglas ^b   Swerdlow, Anthony J ^a   Dowsett, Mitch ^a,v   Pharoah, Paul D ^b   Schmidt, Marjanka K ^u   Garcia Closas, Montserrat ^q   more..

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c Centro Nacional de Investigaciones Oncológicas   (Spain)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^e CANCER EPIDEMIOLOGY CENTRE   (Australia)

^f UNIVERSITY OF MELBOURNE   (Australia)

^g GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^h SAARLAND CANCER REGISTRY   (Germany)

ⁱ UNIVERSITY OF EASTERN FINLAND   (Finland)

^j KUOPIO UNIVERSITY HOSPITAL   (Finland)

^k UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^l UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^m MAYO CLINIC   (United States)

ⁿ LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^o ERASMUS MC CANCER INSTITUTE   (Netherlands)

^p UNIVERSITY OF EDINBURGH   (United Kingdom)

^q NATIONAL CANCER INSTITUTE   (United States)

^r INSTITUTE OF ONCOLOGY   (Poland)

^s SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^t QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^u ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^v ROYAL MARSDEN HOSPITAL   (United Kingdom)

more..

Author keywords

Automated KI67; Breast cancer; Prognostication; Visual KI67

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR; KI 67 ANTIGEN; TUMOR MARKER;

ARTICLE; AUTOMATED KI67 SCORE; BREAST CANCER; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CELL HETEROGENEITY; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; ONCOGENE NEU; SCORING SYSTEM; TISSUE MICROARRAY; TRIPLE NEGATIVE BREAST CANCER; VISUAL KI67 SCORE; ADULT; AGED; BREAST NEOPLASMS; CANCER GRADING; CLINICAL TRIAL; HEALTH SURVEY; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; POPULATION SURVEILLANCE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; YOUNG ADULT;

EID: 84992454911     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/s13058-016-0765-6     Document Type: Article

References (33)

1. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2015;12:296-301. doi:10.1038/nrclinonc.2015.46.
2. Senkus E, Kyriakides S, Penault-Llorca F, Poortmans P, Thompson A, Zackrisson S, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;22:2013.
3. Andre F, Arnedos M, Goubar A, Ghouadni A, Delaloge S. Ki67-no evidence for its use in node-positive breast cancer. Nat Rev Clin Oncol. 2015;12:296-301. doi:10.1038/nrclinonc.2015.46.
4. Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol. 2005;23(28):7212-20.
5. Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 2010;11(2):174-83.
6. de Azambuja E, Cardoso F, de Castro G, Colozza M, Mano MS, Durbecq V, et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients. Br J Cancer. 2007;96(10):1504-13.
7. Stuart-Harris R, Caldas C, Pinder S, Pharoah P. Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. Breast. 2008;17(4):323-34.
8. Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes RC, Cuzick J, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst. 2011;103(22):1656-64.
9. Polley M-YC, Leung SCY, McShane LM, Gao D, Hugh JC, Mastropasqua MG, et al. An International Ki67 Reproducibility Study. J Natl Cancer Inst. 2013;105(24):1897-906.
10. Mikami Y, Ueno T, Yoshimura K, Tsuda H, Kurosumi M, Masuda S, et al. Interobserver concordance of Ki67 labeling index in breast cancer: Japan Breast Cancer Research Group Ki67 Ring Study. Cancer Sci. 2013;104(11):1539-43.
11. Gudlaugsson E, Skaland I, Janssen EAM, Smaaland R, Shao Z, Malpica A, et al. Comparison of the effect of different techniques for measurement of Ki67 proliferation on reproducibility and prognosis prediction accuracy in breast cancer. Histopathology. 2012;61(6):1134-44.
12. Pinder S, Wencyk P, Sibbering D, Bell J, Elston C, Nicholson R, et al. Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival. Br J Cancer. 1995;71(1):146.
13. Pietiläinen T, Lipponen P, Aaltomaa S, Eskelinen M, Kosma V, Syrjänen K. The important prognostic value of Ki-67 expression as determined by image analysis in breast cancer. J Cancer Res Clin Oncol. 1996;122(11):687-92.
14. Fasanella S, Leonardi E, Cantaloni C, Eccher C, Bazzanella I, Aldovini D, et al. Proliferative activity in human breast cancer: Ki-67 automated evaluation and the influence of different Ki-67 equivalent antibodies. Diagn Pathol. 2011;6 Suppl 1:S7.
15. Laurinavicius A, Plancoulaine B, Laurinaviciene A, Herlin P, Meskauskas R, Baltrusaityte I, et al. A methodology to ensure and improve accuracy of Ki67 labelling index estimation by automated digital image analysis in breast cancer tissue. Breast Cancer Res. 2014;16:R35.
16. Tuominen VJ, Ruotoistenmaki S, Viitanen A, Jumppanen M, Isola J. ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67. Breast Cancer Res. 2010;12(4):R56.
17. Konsti J, Lundin M, Joensuu H, Lehtimäki T, Sihto H, Holli K, et al. Development and evaluation of a virtual microscopy application for automated assessment of Ki-67 expression in breast cancer. BMC Clin Pathol. 2011;11(1):3.
18. Mohammed ZMA, McMillan DC, Elsberger B, Going JJ, Orange C, Mallon E, et al. Comparison of visual and automated assessment of Ki-67 proliferative activity and their impact on outcome in primary operable invasive ductal breast cancer. Br J Cancer. 2012;106(2):383-8.
19. Klauschen F, Wienert S, Schmitt WD, Loibl S, Gerber B, Blohmer J-U, et al. Standardized Ki67 diagnostics using automated scoring-clinical validation in the GeparTrio Breast Cancer Study. Clin Cancer Res. 2015;21(16):3651-7.
20. Sheri A, Dowsett M. Developments in Ki67 and other biomarkers for treatment decision making in breast cancer. Ann Oncol. 2012;23 Suppl 10:x219-27.
21. Inwald EC, Klinkhammer-Schalke M, Hofstädter F, Zeman F, Koller M, Gerstenhauer M, et al. Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat. 2013;139(2):539-52.
22. Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E, Zabaglo L, Mallon E, Green AR, Ellis IO, Howell A. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol. 2011;29(32):4273-8.
23. Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E, et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol. 2011;29(32):4273-8.
24. Wishart GC, Bajdik CD, Dicks E, Provenzano E, Schmidt MK, Sherman M, et al. PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2. Br J Cancer. 2012;107(5):800-7.
25. BCAC. Breast Cancer Association Consortium. 19 Aug 2015. http://bcac.ccge.medschl.cam.ac.uk/. Accessed 12 Oct 2016.
26. Abubakar M, Howat WJ, Daley F, Zabaglo L, McDuffus L-A, Blows F, et al. High-throughput automated scoring of Ki67 in breast cancer tissue microarrays from the Breast Cancer Association Consortium. J Pathol Clin Res. 2016;2(3):138-153. doi:10.1002/cjp2.42.
27. Ali AMG, Dawson SJ, Blows FM, Provenzano E, Ellis IO, Baglietto L, et al. Comparison of methods for handling missing data on immunohistochemical markers in survival analysis of breast cancer. Br J Cancer. 2011;104(4):693-9.
28. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817-26.
29. Filipits M, Nielsen TO, Rudas M, Greil R, Stöger H, Jakesz R, et al. The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer. Clin Cancer Res. 2014;20(5):1298-305.
30. Keam B, Im S-A, Lee K-H, Han S-W, Oh D-Y, Kim JH, et al. Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Res. 2011;13(2):R22.
31. Howat WJ, Blows FM, Provenzano E, Brook MN, Morris L, Gazinska P, et al. Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium. Clin J Pathol. 2015;1(1):18-32. doi:10.1002/cjp2.3.
32. Petrelli F, Viale G, Cabiddu M, Barni S. Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients. Breast Cancer Res Treat. 2015;153(3):477-91.
33. Kobierzycki C, Pula B, Wojnar A, Podhorska-Okolow M, Dziegiel P. Tissue microarray technique in evaluation of proliferative activity in invasive ductal breast cancer. Anticancer Res. 2012;32(3):773-7.